Boston Pharmaceuticals Announces Positive Phase 2a Data Supporting Once-monthly Dosing With Investig
BOS-580 treatment improved markers of glycemic control and reduced liver steatosis across diabetic sub-populations with phenotypic NASHAdditional data support the continued development of BOS-580 once-monthly dosingCAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals, a clinical-stage biopharmaceutical company...
Source: pharmiweb.com